<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700791</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0001</org_study_id>
    <nct_id>NCT00700791</nct_id>
  </id_info>
  <brief_title>Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars</brief_title>
  <official_title>Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chandan K Sen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to determine the efficacy of tocotrienol (TCT), a natural&#xD;
      form of vitamin E, in preventing or reducing scar formation in human skin wounds as well as&#xD;
      the basal levels of TCT in normal human skin and adipose tissue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scar formation is the physiological and inevitable end point of mammalian wound healing and&#xD;
      there is substantial evidence that inflammation is an essential prerequisite for scarring.&#xD;
      Although scar tissue restores the normal skin barrier, the new tissue is inferior in&#xD;
      structural, aesthetic, and functional respects. The mammalian wound healing response may have&#xD;
      originated during the time of high susceptibility to infection. Therefore, we may have&#xD;
      developed speed optimized wound healing where a multiple redundant compensating rapid&#xD;
      inflammatory response allows the wound to heal quickly without infection. The scar is then&#xD;
      the price mammals have to pay for evolutionary survival after being wounded.&#xD;
&#xD;
      Tocotrienol may be an effective tool to prevent or reduce normal, hypertrophic, or keloid&#xD;
      scarring by mediating the inflammatory response. Tocotrienol is a safe and convenient&#xD;
      treatment that could be used by mouth or topically. There has never been a study on the&#xD;
      effectiveness of tocotrienol in preventing or reducing scar formation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The PI moved to another Institution&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application</measure>
    <time_frame>4 weeks prior to surgery and 12 weeks post surgery.</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Scar</condition>
  <arm_group>
    <arm_group_label>Group I Single Site Randomization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with 1 surgical scar will be given both oral placebo and topical cream placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II Single Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single surgical site will be given oral placebo and topical TCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III Single Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV Single Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV: Bilateral Site Randomization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Skin and Adipost Tissue Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Normal human skin and adipose tissue will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Natural Vitamin E Tocotrienol supplement (TCT)</intervention_name>
    <description>Oral Vitamin E Tocotrienol Supplement (TCT)</description>
    <arm_group_label>Group III Single Site Randomization</arm_group_label>
    <arm_group_label>Group III: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group IV Single Site Randomization</arm_group_label>
    <arm_group_label>Group IV: Bilateral Site Randomization</arm_group_label>
    <other_name>Oral TCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Natural Vitamin E Tocotrienol Cream (TCT)</intervention_name>
    <description>Natural Vitamin E Tocotrienol(TCT)Topical Cream</description>
    <arm_group_label>Group II Single Site Randomization</arm_group_label>
    <arm_group_label>Group II: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group IV Single Site Randomization</arm_group_label>
    <arm_group_label>Group IV: Bilateral Site Randomization</arm_group_label>
    <other_name>Topical TCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral Placebo</description>
    <arm_group_label>Group I Single Site Randomization</arm_group_label>
    <arm_group_label>Group I: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group II Single Site Randomization</arm_group_label>
    <arm_group_label>Group II: Bilateral Site Randomization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <description>Topical Placebo Cream</description>
    <arm_group_label>Group I Single Site Randomization</arm_group_label>
    <arm_group_label>Group I: Bilateral Site Randomization</arm_group_label>
    <arm_group_label>Group III Single Site Randomization</arm_group_label>
    <arm_group_label>Group III: Bilateral Site Randomization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Non- smoker&#xD;
&#xD;
          -  No current medications that alter liver metabolism (e.g., Phenobarbital, HmG co-A&#xD;
             inhibitors, etc.)&#xD;
&#xD;
          -  Non- pregnant or non-breastfeeding&#xD;
&#xD;
          -  No current use of dietary supplements containing vitamin-E&#xD;
&#xD;
          -  Not actively abusing drugs or alcohol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years of age&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  HIV diagnosis&#xD;
&#xD;
          -  Viral hepatitis diagnosis&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Actively abusing drugs or alcohol&#xD;
&#xD;
          -  Current use of dietary supplements containing vitamin-E&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandan K Sen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OSU Plastic Surgery - Knightsbridge</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Chandan K Sen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Single and bilateral body contouring surgical sites.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

